These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 32034072)

  • 1. Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial.
    Reardon DA; Desjardins A; Vredenburgh JJ; O'Rourke DM; Tran DD; Fink KL; Nabors LB; Li G; Bota DA; Lukas RV; Ashby LS; Duic JP; Mrugala MM; Cruickshank S; Vitale L; He Y; Green JA; Yellin MJ; Turner CD; Keler T; Davis TA; Sampson JH;
    Clin Cancer Res; 2020 Apr; 26(7):1586-1594. PubMed ID: 32034072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
    Weller M; Butowski N; Tran DD; Recht LD; Lim M; Hirte H; Ashby L; Mechtler L; Goldlust SA; Iwamoto F; Drappatz J; O'Rourke DM; Wong M; Hamilton MG; Finocchiaro G; Perry J; Wick W; Green J; He Y; Turner CD; Yellin MJ; Keler T; Davis TA; Stupp R; Sampson JH;
    Lancet Oncol; 2017 Oct; 18(10):1373-1385. PubMed ID: 28844499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.
    Schuster J; Lai RK; Recht LD; Reardon DA; Paleologos NA; Groves MD; Mrugala MM; Jensen R; Baehring JM; Sloan A; Archer GE; Bigner DD; Cruickshank S; Green JA; Keler T; Davis TA; Heimberger AB; Sampson JH
    Neuro Oncol; 2015 Jun; 17(6):854-61. PubMed ID: 25586468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma.
    Gatson NT; Weathers SP; de Groot JF
    CNS Oncol; 2016; 5(1):11-26. PubMed ID: 26670466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospect of rindopepimut in the treatment of glioblastoma.
    Elsamadicy AA; Chongsathidkiet P; Desai R; Woroniecka K; Farber SH; Fecci PE; Sampson JH
    Expert Opin Biol Ther; 2017 Apr; 17(4):507-513. PubMed ID: 28274144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.
    Paff M; Alexandru-Abrams D; Hsu FP; Bota DA
    Hum Vaccin Immunother; 2014; 10(11):3322-31. PubMed ID: 25625931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.
    Swartz AM; Li QJ; Sampson JH
    Immunotherapy; 2014; 6(6):679-90. PubMed ID: 25186601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme.
    Del Vecchio CA; Wong AJ
    Curr Opin Mol Ther; 2010 Dec; 12(6):741-54. PubMed ID: 21154166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma.
    Babu R; Adamson DC
    Core Evid; 2012; 7():93-103. PubMed ID: 23055947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872.
    Galanis E; Anderson SK; Twohy EL; Carrero XW; Dixon JG; Tran DD; Jeyapalan SA; Anderson DM; Kaufmann TJ; Feathers RW; Giannini C; Buckner JC; Anastasiadis PZ; Schiff D
    Cancer; 2019 Nov; 125(21):3790-3800. PubMed ID: 31290996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
    Brandes AA; Gil-Gil M; Saran F; Carpentier AF; Nowak AK; Mason W; Zagonel V; Dubois F; Finocchiaro G; Fountzilas G; Cernea DM; Chinot O; Anghel R; Ghiringhelli F; Beauchesne P; Lombardi G; Franceschi E; Makrutzki M; Mpofu C; Urban HJ; Pichler J
    Oncologist; 2019 Apr; 24(4):521-528. PubMed ID: 30266892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rindopepimut vaccine and bevacizumab combination therapy: improving survival rates in relapsed glioblastoma patients?
    Neagu MR; Reardon DA
    Immunotherapy; 2015; 7(6):603-6. PubMed ID: 26100271
    [No Abstract]   [Full Text] [Related]  

  • 13. Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic.
    Gedeon PC; Choi BD; Sampson JH; Bigner DD
    Drugs Future; 2013 Mar; 38(3):147-155. PubMed ID: 25663738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas.
    Del Vecchio CA; Li G; Wong AJ
    Expert Rev Vaccines; 2012 Feb; 11(2):133-44. PubMed ID: 22309662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Not Yet Another Negative Trial-ReACTing on Recent Glioblastoma Trials.
    Wick W; Wagener RJ
    Clin Cancer Res; 2020 Apr; 26(7):1535-1537. PubMed ID: 32034079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
    Field KM; Simes J; Nowak AK; Cher L; Wheeler H; Hovey EJ; Brown CS; Barnes EH; Sawkins K; Livingstone A; Freilich R; Phal PM; Fitt G; ; Rosenthal MA
    Neuro Oncol; 2015 Nov; 17(11):1504-13. PubMed ID: 26130744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
    Lee EQ; Reardon DA; Schiff D; Drappatz J; Muzikansky A; Grimm SA; Norden AD; Nayak L; Beroukhim R; Rinne ML; Chi AS; Batchelor TT; Hempfling K; McCluskey C; Smith KH; Gaffey SC; Wrigley B; Ligon KL; Raizer JJ; Wen PY
    Neuro Oncol; 2015 Jun; 17(6):862-7. PubMed ID: 25572329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma.
    Ghiaseddin A; Reardon D; Massey W; Mannerino A; Lipp ES; Herndon JE; McSherry F; Desjardins A; Randazzo D; Friedman HS; Peters KB
    Oncologist; 2018 Feb; 23(2):157-e21. PubMed ID: 29133513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4
    Bota DA; Chung J; Dandekar M; Carrillo JA; Kong XT; Fu BD; Hsu FP; Schönthal AH; Hofman FM; Chen TC; Zidovetzki R; Pretto C; Strik A; Schijns VE; Stathopoulos A
    CNS Oncol; 2018 Jul; 7(3):CNS22. PubMed ID: 30157683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.